ES2118955T3 - Derivados de dolastatina. - Google Patents

Derivados de dolastatina.

Info

Publication number
ES2118955T3
ES2118955T3 ES93909931T ES93909931T ES2118955T3 ES 2118955 T3 ES2118955 T3 ES 2118955T3 ES 93909931 T ES93909931 T ES 93909931T ES 93909931 T ES93909931 T ES 93909931T ES 2118955 T3 ES2118955 T3 ES 2118955T3
Authority
ES
Spain
Prior art keywords
dolastatin derivatives
derivatives
new
dolastatin
dolastatine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909931T
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Application granted granted Critical
Publication of ES2118955T3 publication Critical patent/ES2118955T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBEN NUEVOS DERIVADOS DE DOLASTATINA DE FORMULA (I), EN LA QUE R1, R2, A, B, D, E, F, G, K, X, T, U, V, Y W TIENEN LOS SIGNIFICADOS ESTABLECIDOS EN LA DESCRIPCION, Y LA PREPARACION DE LOS MISMOS. LAS SUSTANCIAS NUEVAS TIENEN UN EFECTO ANTINEOPLASTICO.
ES93909931T 1992-05-20 1993-05-10 Derivados de dolastatina. Expired - Lifetime ES2118955T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88578892A 1992-05-20 1992-05-20
US98569692A 1992-11-25 1992-11-25

Publications (1)

Publication Number Publication Date
ES2118955T3 true ES2118955T3 (es) 1998-10-01

Family

ID=27128772

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909931T Expired - Lifetime ES2118955T3 (es) 1992-05-20 1993-05-10 Derivados de dolastatina.

Country Status (21)

Country Link
EP (1) EP0642530B1 (es)
JP (2) JP3523253B2 (es)
KR (1) KR100286242B1 (es)
CN (1) CN1065874C (es)
AT (1) ATE169637T1 (es)
AU (1) AU669710B2 (es)
CA (1) CA2136339C (es)
CZ (1) CZ292612B6 (es)
DE (1) DE69320339T2 (es)
DK (1) DK0642530T3 (es)
ES (1) ES2118955T3 (es)
FI (1) FI120692B (es)
HU (2) HUT71398A (es)
IL (1) IL105651A (es)
MX (1) MX9302927A (es)
NO (1) NO310465B1 (es)
NZ (1) NZ252147A (es)
RU (1) RU2116312C1 (es)
SI (1) SI9300267A (es)
UA (1) UA45304C2 (es)
WO (1) WO1993023424A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
DE19527575A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
DE19527574A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung vona-(N,N-Dialkyl)-aminocaarbonsäureamiden
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
AU775090B2 (en) * 1995-12-15 2004-07-15 Abbvie Deutschland Gmbh & Co Kg Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
EP1049481B1 (en) * 1997-09-24 2005-04-20 Arizona Board Of Regents Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
DE04811862T1 (de) 2003-11-24 2006-03-02 Teva Gyogyszergyar Reszvenytarsasag Verfahren zur Reinigung von Pravastatin
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
KR0185440B1 (ko) * 1991-08-09 1999-04-01 야마구찌 다까시 신규의 테트라 펩티트 유도체

Also Published As

Publication number Publication date
SI9300267A (sl) 1993-12-31
JP3523253B2 (ja) 2004-04-26
HU211745A9 (en) 1995-12-28
NO310465B1 (no) 2001-07-09
NZ252147A (en) 1996-10-28
JPH07506580A (ja) 1995-07-20
RU94046434A (ru) 1996-10-27
EP0642530B1 (en) 1998-08-12
CZ292612B6 (cs) 2003-11-12
FI120692B (fi) 2010-01-29
CA2136339A1 (en) 1993-11-25
HUT71398A (en) 1995-11-28
AU669710B2 (en) 1996-06-20
UA45304C2 (uk) 2002-04-15
ATE169637T1 (de) 1998-08-15
EP0642530A1 (en) 1995-03-15
MX9302927A (es) 1993-11-01
NO944419D0 (no) 1994-11-18
KR100286242B1 (ko) 2001-04-16
AU4066293A (en) 1993-12-13
DE69320339D1 (de) 1998-09-17
NO944419L (no) 1995-01-09
DK0642530T3 (da) 1998-10-26
CN1085563A (zh) 1994-04-20
IL105651A0 (en) 1993-09-22
CN1065874C (zh) 2001-05-16
JP2004149538A (ja) 2004-05-27
WO1993023424A1 (en) 1993-11-25
FI945416L (fi) 1994-11-17
IL105651A (en) 1998-07-15
FI945416A0 (fi) 1994-11-17
RU2116312C1 (ru) 1998-07-27
CA2136339C (en) 2008-02-05
CZ284394A3 (en) 1995-05-17
DE69320339T2 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
ES2188759T3 (es) Derivados de la dolastatina, su preparacion y su uso.
ES2118955T3 (es) Derivados de dolastatina.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9203027A (es) Derivados heterociclicos de acilaminotiazoles y composicines farmaceuticas que los contienen.
AR001592A1 (es) Composicion herbicida y metodo de control de malezas
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
MX9700557A (es) Dihidrobenzofuranos.
DE69332079D1 (de) Prothetische ligamente
FI952961A0 (fi) Dolostatiinianalogeja
ES2146297T3 (es) Nuevos derivados del benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9204563A (es) Nuevos derivados de la (2-alquil-3-piridil)-metilpiperazina y composicion farmaceutica que los comprende.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY24915A1 (es) Derivados de benzoxazindiona, aplicación de los mismos y medicamentos que los contienen
MX9203616A (es) Derivados de 4-amidino cromano y de 4-amidino[3,2-c] piridina y composiciones farmaceuticas que los contienen.
ES2105633T3 (es) Derivados de pirimidinona condensada a heterociclos nitrogenados con actividad antagonista de a ii.
ATE57526T1 (de) P-acylaminobenzamide.
DK242089A (da) Anvendelse af pyrimido oe6,1-aaa-isoquinolin-4-on-derivater til hindring af haaraffald og foroegelse af haarvaekst
DK308582A (da) 10-(1-aza(2,2,2)-bicyklo-3-octyl)-10h-2-phenothiazinsulfonamid og derivater
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
AR004382A1 (es) Peptidos, su obtencion y las composiciones farmaceuticas que los contienen.
DE3884363D1 (de) Ethanolaminderivate.
ES2084724T3 (es) 3'-desamino-4'-desoxi-4'-amino-8-fluoroantraciclinas y procedimientos de preparacion.
MX9102369A (es) 2,6-alcoxifenil-alquilcetonas y composicion herbicida que las contiene.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642530

Country of ref document: ES